Buying & Supplying

GSK puts Lucozade and Ribena under review

By 2013-02-06T16:01:00

LUCOZADE

GlaxoSmithKline is reviewing “all strategic options” for its Lucozade and Ribena brands as it continues to overhaul its European business.

 

Already have an account? Sign in here

You’ve used up your article allowance

Sign up to read more stories for free

Register now